Page last updated: 2024-11-11

(melle-4)cyclosporin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

(melle-4)cyclosporin: a non-immunosuppressive analog of cyclosporin A [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6473876
CHEMBL ID1688529
SCHEMBL ID14670015
MeSH IDM0238965

Synonyms (32)

Synonym
sdz-nim-811
[n-meile4]-cyclosporin
nim-811
sdz nim 811
[me-ile-4]cyclosporin a
[meile]4-ciclosporin
[meile]4-cyclosporin
[meile]4-csa
nim 811
nim811
(3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-33-[(e,1r,2r)-1-hydroxy-2-methyl-hex-4-enyl]-6,9,18-triisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-24-[(1s)-1-methylpropyl]-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11
143205-42-9
CHEMBL1688529 ,
(3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-24-[(2s)-butan-2-yl]-30-ethyl-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-
bdbm50339126
(3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-24-sec-butyl-30-ethyl-33-((1r,2r)-1-hydroxy-2-methylhex-4-enyl)-6,9,18-triisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26
9-(n-methyl-l-isoleucine)-cyclosporin a
(melle-4)cyclosporin
sdz nim811
unii-96262s4i14
cyclosporin a, 9-(n-methyl-l-isoleucine)-
9-(n-methyl-l-isoleucine)cyclosporin a
96262s4i14 ,
CS-8062
HY-P0025
SCHEMBL14670015
DB13068
DTXSID70904006
sdz nim811; (melle-4)cyclosporin
Q6954330
MS-32042
AKOS040733857

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" There were no severe or serious adverse events."( Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy.
Evans, TG; Godofsky, E; Huang, M; Ke, J; Lawitz, E; Marbury, T; Nguyen, T; Praestgaard, J; Rouzier, R; Serra, D, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
" Therefore, to build upon these results, a severe unilateral controlled cortical impact model of TBI was used in the present study to establish a dose-response curve for NIM811 in rats."( Post-injury administration of the mitochondrial permeability transition pore inhibitor, NIM811, is neuroprotective and improves cognition after traumatic brain injury in rats.
McEwen, ML; Pandya, JD; Pauly, JR; Readnower, RD; Springer, JE; Sullivan, PG, 2011
)
0.37
" Because the safe limit of APAP dosing is controversial, our aim was to evaluate the role of the mitochondrial permeability transition (MPT) and JNK in mitochondrial dysfunction after APAP dosing considered nontoxic by criteria of serum alanine aminotransferase (ALT) release and histological necrosis in vivo."( Low Dose Acetaminophen Induces Reversible Mitochondrial Dysfunction Associated with Transient c-Jun N-Terminal Kinase Activation in Mouse Liver.
Hu, J; Jaeschke, H; Lemasters, JJ; McGill, MR; Ramshesh, VK, 2016
)
0.43
" In the present study, we conducted a dose-response examination of NIM811, a nonimmunosuppressive CsA analog, on recovery of function and tissue sparing in a rat model of moderate to severe SCI."( Post-Injury Treatment with NIM811 Promotes Recovery of Function in Adult Female Rats after Spinal Cord Contusion: A Dose-Response Study.
Hall, ED; Springer, JE; Sullivan, PG; Visavadiya, NP, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Peptidyl-prolyl cis-trans isomerase A Homo sapiens (human)Ki0.00210.00030.04730.2310AID581778
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Peptidyl-prolyl cis-trans isomerase BHomo sapiens (human)Kd0.00740.00100.00530.0098AID1168835
Peptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)Kd0.00420.00100.00280.0042AID1168836
Peptidyl-prolyl cis-trans isomerase A Homo sapiens (human)Kd0.00750.00220.42976.4200AID1168824
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (53)

Processvia Protein(s)Taxonomy
chaperone-mediated protein foldingPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
regulation of post-translational protein modificationPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
protein peptidyl-prolyl isomerizationPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
neutrophil chemotaxisPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
positive regulation of multicellular organism growthPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
positive regulation by host of viral processPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
positive regulation by host of viral genome replicationPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
protein stabilizationPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
bone developmentPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
chaperone-mediated protein foldingPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
protein foldingPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
protein peptidyl-prolyl isomerizationPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
response to ischemiaPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
apoptotic mitochondrial changesPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
regulation of proton-transporting ATPase activity, rotational mechanismPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
negative regulation of ATP-dependent activityPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
negative regulation of apoptotic processPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
regulation of mitochondrial membrane permeabilityPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
mitochondrial depolarizationPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
necroptotic processPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
cellular response to hydrogen peroxidePeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
cellular response to arsenic-containing substancePeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
cellular response to calcium ionPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
negative regulation of release of cytochrome c from mitochondriaPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
negative regulation of oxidative phosphorylationPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
skeletal muscle fiber differentiationPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
regulation of mitochondrial membrane permeability involved in programmed necrotic cell deathPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
mitochondrial outer membrane permeabilization involved in programmed cell deathPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
negative regulation of oxidative phosphorylation uncoupler activityPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
protein foldingPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
protein peptidyl-prolyl isomerizationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
negative regulation of protein phosphorylationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
positive regulation of protein phosphorylationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
protein foldingPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
negative regulation of protein kinase activityPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
apoptotic processPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
viral release from host cellPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
platelet activationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
neuron differentiationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
neutrophil chemotaxisPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
leukocyte chemotaxisPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
activation of protein kinase B activityPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
negative regulation of stress-activated MAPK cascadePeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
lipid droplet organizationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
cellular response to oxidative stressPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
positive regulation of protein dephosphorylationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
endothelial cell activationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
positive regulation of MAPK cascadePeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
regulation of viral genome replicationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
positive regulation of viral genome replicationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
positive regulation of protein secretionPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
cell adhesion molecule productionPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
negative regulation of protein K48-linked ubiquitinationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
platelet aggregationPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
negative regulation of viral life cyclePeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
regulation of apoptotic signaling pathwayPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
collagen bindingPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
RNA bindingPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
peptidyl-prolyl cis-trans isomerase activityPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
protein bindingPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
cyclosporin A bindingPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
unfolded protein bindingPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
RNA polymerase bindingPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
peptidyl-prolyl cis-trans isomerase activityPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
protein bindingPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
cyclosporin A bindingPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
peptide bindingPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
RNA bindingPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
peptidyl-prolyl cis-trans isomerase activityPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
integrin bindingPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
protein bindingPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
cyclosporin A bindingPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
virion bindingPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
unfolded protein bindingPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
heparan sulfate bindingPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (24)

Processvia Protein(s)Taxonomy
nucleusPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
nucleoplasmPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
endoplasmic reticulumPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
endoplasmic reticulum lumenPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
smooth endoplasmic reticulumPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
cytosolPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
focal adhesionPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
membranePeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
melanosomePeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
perinuclear region of cytoplasmPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
extracellular exosomePeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
protein-containing complexPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
endoplasmic reticulum chaperone complexPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
intracellular membrane-bounded organellePeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
cytoplasmPeptidyl-prolyl cis-trans isomerase BHomo sapiens (human)
mitochondrial proton-transporting ATP synthase complexPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
mitochondrionPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
mitochondrial matrixPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
membranePeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
mitochondrial permeability transition pore complexPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
cytoplasmPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
mitochondrionPeptidyl-prolyl cis-trans isomerase F, mitochondrialHomo sapiens (human)
extracellular regionPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
extracellular spacePeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
nucleusPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
cytoplasmPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
cytosolPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
focal adhesionPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
membranePeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
vesiclePeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
secretory granule lumenPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
extracellular exosomePeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
ficolin-1-rich granule lumenPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
protein-containing complexPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
cytoplasmPeptidyl-prolyl cis-trans isomerase A Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID1168835Binding affinity to human cyclophilin B by surface plasmon resonance method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID762654Antiviral activity against HIV1 3B infected in human MT4 cells coinfected with HTLV1 assessed as reduction in virus-induced cytopathogenicity after 4 days by MTT assay2013Bioorganic & medicinal chemistry letters, Aug-15, Volume: 23, Issue:16
Cyclophilin inhibitors as antiviral agents.
AID523619Antiviral activity against HCV subtype 1b Con1 harboring NS5A C575G mutant protease infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by qRT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.
AID1168840Cytotoxicity against PHA-stimulated human PBMC by 5-bromo-2'-deoxyuridine incorporation assay2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID581771Cytotoxicity against human MT4 cells at 0.83 uM by MTT assay2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1168836Binding affinity to human cyclophilin F by surface plasmon resonance method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID581778Inhibition of human recombinant cyclophilin-associted cis-trans propyl isomerase activity2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID523618Antiviral activity against HCV subtype 1b Con1 harboring wild type protease infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by qRT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.
AID1178322Antiviral activity against HCV infected in human patient assessed as log reduction in viral RNA at 600 mg, bid co-treated with interferon measured 7 days after treatment2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
From chemical tools to clinical medicines: nonimmunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds.
AID581770Cytotoxicity against human PBMC at 0.83 uM by MTT assay2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID523613Antiviral activity against wild type HCV subtype 1b Con1 infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by qRT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.
AID1168839Cytotoxicity against human MT4 cells by CDCF probe based assay2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID581774Antiviral activity against HIV-1 SF2 infected in human PBMC assessed as inhibition of viral replication by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1168825Antiviral activity against HCV subtype 1b in human Huh7.5 cells expressing subgenomic HCV replicons and coexpressing luciferase reporter gene2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID523616Antiviral activity against cyclosporine A/NIM811-resistant HCV subtype 1b Con1 infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by qRT-PCR analysis relative to control2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.
AID523610Antiviral activity against cyclosporine A-resistant HCV subtype 1b Con1 infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by MTS assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.
AID523611Antiviral activity against cyclosporine A/NIM-resistant HCV subtype 1b Con1 infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by MTS assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.
AID1168824Binding affinity to human cyclophilin A by surface plasmon resonance method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID1168838Antiviral activity against HCV subtype 1b in human Huh7.5 cells expressing subgenomic HCV replicons and coexpressing luciferase reporter gene in presence of 40% human serum2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID581769Immunosuppressive activity in human Jurkat cells assessed as inhibition of PHA-phorbol myristate acetate induced beta-galactosidase activity at 6.75 uM2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID523617Antiviral activity against HCV subtype 1b Con1 infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by qRT-PCR analysis relative to control2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.
AID523612Antiviral activity against HCV subtype 1b Con1 infected in cyclosporine A/NIM-resistant human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by qRT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.
AID581777Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect by MTT assay2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581776Antiviral activity against HIV-1 3B infected in human PBMC assessed as inhibition of viral replication by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1168837Antiviral activity against HCV subtype 1a in human Huh7.5 cells expressing subgenomic HCV replicons and coexpressing luciferase reporter gene2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID523620Antiviral activity against HCV subtype 1b Con1 harboring NS5A and NS5B C575G mutant protease infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by qRT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.
AID523615Antiviral activity against HCV subtype 1b Con1 infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by qRT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.
AID523614Antiviral activity against cyclosporine A/NIM811-resistant HCV subtype 1b Con1 infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by qRT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (81)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's8 (9.88)18.2507
2000's28 (34.57)29.6817
2010's42 (51.85)24.3611
2020's3 (3.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.54 (24.57)
Research Supply Index4.43 (2.92)
Research Growth Index4.97 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.22%)5.53%
Reviews6 (7.32%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other75 (91.46%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]